JaLCDOI 10.18926/AMO/57959
FullText URL 74_1_89.pdf
Author Kada, Akiko| Fukano, Reiji| Mori, Tetsuya| Kamei, Michi| Tanaka, Fumiko| Ueyama, Junichi| Sekimizu, Masahiro| Osumi, Tomoo| Mori, Takeshi| Koga, Yuhki| Ohki, Kentaro| Fujita, Naoto| Mitsui, Tetsuo| Saito, Akiko M.| Hashimoto, Hiroya| Kobayashi, Ryoji|
Abstract No standard treatment for relapsed or refractory anaplastic large-cell lymphoma (ALCL) has been established. This study is a multicenter, open-label trial to examine the effectiveness and safety of transplantation with reduced-intensity conditioning (RIC) for patients under 20 years old with relapsed or refractory ALCL. We defined RIC as the administration of fludarabine (30 mg/m2/day) for five days plus melphalan (70 mg/m2/day) for two days and total body irradiation at 4 Gy, followed by allogeneic hematopoietic stem cell transplantation.
Keywords anaplastic large-cell lymphoma relapsed/refractory fludarabine melphalan total body irradiation
Amo Type Clinical Study Protocol
Published Date 2020-02
Publication Title Acta Medica Okayama
Volume volume74
Issue issue1
Publisher Okayama University Medical School
Start Page 89
End Page 94
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2020 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 32099255
JaLCDOI 10.18926/AMO/56185
FullText URL 72_4_437.pdf
Author Koga, Yuhki| Baba, Shingo| Fukano, Reiji| Nakamura, Katsumasa| Soejima, Toshinori| Maeda, Naoko| Sunami, Shosuke| Ueyama, Junichi| Mitsui, Tetsuo| Mori, Takeshi| Osumi, Tomoo| Sekimizu, Masahiro| Ohki, Kentaro| Tanaka, Fumiko| Kamei, Michi| Fujita, Naoto| Mori, Tetsuya| Saito, Akiko M.| Kada, Akiko| Kobayashi, Ryoji|
Abstract This trial enrolls patients with untreated Hodgkin’s lymphoma aged<20 years at diagnosis and examines the effects of omitting radiation therapy if the FDG-positron emission tomography (PET) findings after two completed cycles of combination chemotherapy are negative. It thereby aims to determine whether patients who truly require radiation therapy can be identified by FDG-PET. If so, this modality could be used to omit radiation therapy for all other patients, decreasing the risk of serious long-term complications without affecting survival rates. The outcomes of patients for whom FDG-PET is used to assess early treatment response will also be determined.
Keywords Hodgkin’s lymphoma pediatric fludeoxyglucose positron emission tomography
Amo Type Clinical Study Protocol
Published Date 2018-08
Publication Title Acta Medica Okayama
Volume volume72
Issue issue4
Publisher Okayama University Medical School
Start Page 437
End Page 440
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2018 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 30140095